Pfizer Acquires Metsera, Expects GLP-1 Drugs to Hit Market by 2028

Pfizer CEO Albert Bourla expects Metsera's GLP-1 products to hit the market as early as 2028 after acquiring the smaller obesity drug maker for up to $10 billion. Bourla believes Metsera's MET-097i, a monthly injectable GLP-1, will be market-leading and that Pfizer is the right company to bring it to market. The acquisition is expected to be dilutive through 2030.